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Circumsporozoite protein (CSP) variants of P. vivax, besides having variations in the 
protein repetitive portion, can differ from each other in aspects such as geographical 
distribution, intensity of transmission, vectorial competence and immune response. 
Such aspects must be considered to P. vivax vaccine development. Therefore, we 
evaluated the immunogenicity of novel recombinant proteins corresponding to each 
of the three P. vivax allelic variants (VK210, VK247 and P. vivax-like) and of the C-
terminal region (shared by all PvCSP variants) in naturally malaria-exposed 
populations of Brazilian Amazon. Our results demonstrated that PvCSP-VK210 was 
the major target of humoral immune response in studied population, presenting 
higher frequency and magnitude of IgG response. The IgG subclass profile showed a 
prevalence of cytophilic antibodies (IgG1 and IgG3), that seem to have an essential 
role in protective immune response. Differently of PvCSP allelic variants, antibodies 
elicited against C-terminal region of protein did not correlate with epidemiological 
parameters, bringing additional evidence that humoral response against this protein 
region is not essential to protective immunity. Taken together, these findings increase 
the knowledge on serological response to distinct PvCSP allelic variants and may 




Plasmodium, a complex multi-stage organism, has specialized proteins that promote 
the parasite’s survival in both vertebrate and invertebrate hosts and support the 
invasion of multiple cell types. Vaccines targeting sporozoites correspond to an 
attractive strategy widely explored since fewer than 100 sporozoites are inoculated in 
human host during the blood meal of infected female Anopheles mosquito 1. 
Moreover, it was already demonstrated that in mice 2, non-human primates 1,2 and 
humans 3, the immunization using irradiated sporozoites is capable to elicit protective 
immunity. 
 
Despite the broad investigation of various proteins as vaccine candidates, the 
circumsporozoite surface protein (CSP) remains in the lead because it was described 
as sporozoites’ major surface protein and it has a crucial role in sporozoite’s motility 
and hepatocyte invasion 4,5. It has been reported that the CSP play a vital role in 
invading to the mosquito's salivary glands, binding sporozoite to liver cells, and 
inactivating the host cell protein synthesis machinery 6. It has already been 
demonstrated that specific antibodies against the P. falciparum circumsporozoite 
protein (PfCSP), present in the serum of vaccinated mice, rhesus macaques and 
humans, have the ability to block sporozoite invasion of hepatocytes 7. Structurally, 
CSP contains approximately 400 amino acids and is organized into three domains: 
The N-terminal, which contain the conserved pentapeptide (region I); a highly 
repetitive species-specific central domain (repetitive region) and a conserved C-
terminal domain (region II).  
 
Currently, the most advanced malaria vaccine is the RTS,S, manufactured by 
GlaxoSmithKline (GSK). RTS,S, produced in Saccharomyces cerevisiae, consists in 
a recombinant vaccine comprising PfCSP’s C-terminal and repeat regions in 
combination with hepatitis B virus’ surface antigen (S) 8. This already licensed 
vaccine is being implemented since 2018 in selected areas of Ghana, Kenya and 
Malawi 9,10. On the other hand, such as almost all vaccine candidates currently 
tested, this vaccine targets only P. falciparum. The priority given to falciparum 
malaria results from the ability of this plasmodial species in producing elevated 
parasite loads and to invade red blood cells in all stages, causing extensive morbidity 
and mortality 11. Nevertheless, some particularities of P. vivax, such as the increasing 
numbers of reports of severe vivax malaria 12-15 and the appearance of strains 
resistant to treatment 16-18, highlight the importance of the development of a specific 
vaccine against P. vivax. 
 
In contrast to PfCSP, P. vivax CSP (PvCSP) is polymorphic and has three allelic 
variants. Analyses in PvCSP genotypes demonstrated the existence of sequence 
repeats of this protein belonging to one of two types of nonapeptide repeat units 
known as VK210 (GDRA(A/D)GQPA) and VK247 (ANGA(G/D)(N/D)QPG) 19,20. In 
addition, a third variant, identified by Qary et al 21 as P. vivax-like, is different from 
both nonapeptide variants, and it is composed by a repeat sequence of 11-mer – 
APGANQ(E/G)GGAA –. Phylogenetic and serological study conducted by Souza-
Neiras et al 22, has demonstrated that differences in these three variants are strictly 
present in the central repeats of the protein, but present several nucleotide variations 
with important serological impact. Therefore, it should be considered for PvCSP 
vaccine trials once they represent important intra-specific biological signatures. In 
Brazil, the prevalence of PvCSP allelic variants was previously studied and is known 
in several states such as Acre, Amazonas, Belém, Macapá, Mato Grosso, Pará, 
Porto Velho and Rondônia 23,24.  
Although less investigated than PfCSP, P. vivax CSP began to receive more 
attention in recent years and strategies were developed to overcome the variations in 
central domain. An example is the Escherichia coli expressed vaccine VMP001, 
which encodes a chimeric CSP and contains sequences with repetitions of alleles 
VK210 and VK247. This vaccine went into clinical testing and was capable of 
inducing recognition, agglutination and virulence loss of live sporozoites, due to the 
high levels of antibodies induced 25. Salman et al also reported the deployment of a 
highly protective P. vivax vaccine, composed by Salvador I sequences of CSP, 
including its C-terminal region and central repeats of VK210 and VK247, on the 
surface of a virus-like particle (VLP) based on the Hepatitis B surface antigen, overall 
known as Rv21. This vaccine was used in rodent model challenges with transgenic 
sporozoites, where it was capable to achieve 100% sterile protection 26. In the 
present study, the naturally acquired humoral immune response to PvCSP repeat 
variants was evaluated in exposed populations of three regions in the Brazilian 
Amazon, using recombinant proteins for each one of the three alleles already 
described. We have also determined the antibody subclass profile induced by 
different PvCSP variants and verified the associations between the specific IgG and 
its subclasses (IgG1, IgG2, IgG3 ad IgG4) with epidemiological characteristics that 




Epidemiological profile of the studied population 
299 individuals living in three different endemic areas of Brazilian Amazon composed 
our study population (Cruzeiro do Sul, Guajará and Mâncio Lima). The population 
age ranged from 12 to 88 years old (median 32 years) and presented similar 
frequencies of female and male individuals. Studied individuals have been naturally 
exposed to malaria infection, have been living in endemic areas for 31 years (ranging 
from 3 to 88 years), most frequently in the same address (0 to 88 years, median 20 
years) and reporting, for 86% of the population, at least one previous malaria 
episode. P. vivax was the most prevalent species, together this species mono-
infections and mixed infections corresponded to 65.2% of cases diagnosed during 
the period of study (p<0.0001), and to the leading cause of previous malaria 
episodes in 81% of studied individuals. The control group composed by 53 
individuals from the non-endemic area of Rio de Janeiro, who never reported malaria 
episodes, was composed by 69,8% female and 30,2% male, ranging from 17 to 43 
years old (median 20 years). The analysis of individual populations based on 
localities studied (Table 1) reveals a similar profile in relation to time of exposure, 
number of past malaria infections and diagnosis at the time of blood collection. 
However, volunteers residing in Guajará (GJ) presented longer time since the last 
malaria episode (median 12 months) than those of Cruzeiro do Sul (median 2.5 
months) and Mâncio Lima (median 3.5 months; p=0.0044 and 0.0001, respectively). 
 
Design of the vCSP proteins and assessment of protein secretion for 
purification. 
Serological analysis of the immune response to malarial antigens is paramount to 
establish the immunogenicity of potential vaccine candidates and the immune 
competence or even the effect of parasite genetic polymorphisms in the immunity of 
residing populations in a given geographical location. However, most of the studies 
conduct ELISAS against the full-length protein of interest. Here we sought to dissect 
the serological immune responses against vivax CSP malaria by constructing 
expression plasmids encoding the sole central repeats of each of the allelic variants 
of VK247, VK210 and V-Like, respectively, and the C-terminal region of CSP (Figure 
1). The design of these sub-domain regions is based in the antigenic conformation of 
the chimeric CSP 210/247 from the Rv21 vaccine 26 which also contains the highly 
conserved C-Terminal region of vCSP. For the case of the Vivax-Like repeats we 
used a sequence previously reported 26. Figure 1a shows a diagrammatic 
representation of vCSP and the four subunits that were synthesized and enzyme-
digested to ligate (Figure 1b) into the expression plasmid PhLSec. After ligation with 
the PhLsec backbone, bacterial transformants were double-digested to verify the 
right size of the transgenes (Figure 1c). The red and black asterisks denote the 
specific size of each transgene and the PhLSec backbone, respectively. Upon 
confirmation of the right clones by enzymatic digestion, plasmids were further verified 
by Sanger-sequencing. PhLsec plasmids were then transfected into HEK293 cells 
and supernatant was recovered to assess the secretion capabilities of our c-tagged 
vCSP subunits. Supernatants were subjected to western blot analysis using a 
camelid anti-C-Tag antibody (Figure 1d). Specific bands were detected for the C-
term, VK247 and Vivax-Like as well as in the unrelated NS1 beta ladder protein fused 
to EPEA (c-tag). No bands were detected in the negative untransfected cells or in the 
unrelated PhLsec plasmid fused to His-tag. However, the anti-C-Tag antibody failed 
to recognize the VK210 repeats, suggesting a masking effect inflicted by the protein-
resolving conditions. To further investigate this masking effect, we used specific 
monoclonal antibodies (mAb) targeting the VK210 (Figure 1e) and the VK247 (Figure 
1f) repeats, respectively. By using the anti-210 mAb, we detected a strong signal in 
the sample that was negative in the C-tag western blot, and not in the other 
transfectant supernatants, thus confirming the secretion capabilities of VK210 
repeats (Figure 1e). On the other hand, when using the anti-247 antibody, we 
detected abundant signal in the lane corresponding to the VK247 supernatants, thus 
confirming the secretion of the VK247 repeats (Figure 1f). A non-specific band of 35 
Kda was detected in all samples. Therefore, the design of the expression plasmids 
allows the expression and the secretion of the vCSP subunits for a subsequent 
protein-column purification, to be used as coating agents in the ELISA assays. 
Frequency and magnitude of IgG antibodies to recombinant proteins derived 
from PvCSP 
We assessed the naturally acquired IgG response against PvCSP recombinant 
central repeats of PvCSP-VK210, PvCSP-VK247, and PvCSP-P. vivax-like, as well 
as the PvCSP-C terminal region, in 299 exposed individuals. Firstly, we evaluated the 
frequency of responders to recombinant PvCSPs in each studied community (Figure 
2a). In Cruzeiro do Sul (CZS), the frequencies of responders to PvCSP allelic 
variants (PvCSP-VK210, PvCSP-VK247, PvCSP-P. vivax-like) were quite similar 
(52%, 42% and 40%, respectively), while in Guajará (GJ) we observed higher 
frequencies of responders to PvCSP-VK210 (63%) and PvCSP-P. vivax-like (57%) 
than frequencies of responders to PvCSP-VK247 (24%) (p<0.0001 and p<0.0001, 
respectively) and to PvCSP-Ct (31%) (p<0.0001 and p=0.0007, respectively). 
Moreover, in Mâncio Lima community (ML), we observed a prevalence of responders 
to PvCSP-VK210 (65%) when compared to frequency of responders to PvCSP-
VK247 (33%, p<0.0001), PvCSP-P.vivax-like (48%, p=0.0331) and to PvCSP-Ct 
(34%, p<0.0001). In relation to the magnitude of response to different recombinant 
PvCSP among responders, despite differences in epidemiological data and 
frequencies of responders in each studied location, similar IgG reactivity indexes 
against PvCSP variants and PvCSP-Ct were observed in all studied populations 
(Figure 2b). Based on the absence of statistical differences among IgG reactivity 
indexes against recombinant proteins in these three studied places, we decided to 
analyze them as a single population. Responders to PvCSP-VK210 (n = 177; 59%) 
were more prevalent when compared to responders to PvCSP-VK247 (n=102, 34%; 
p<0.0001), to PvCSP-P. vivax-like (n=141, 47%; p=0.0041) and to PvCSP-Ct (n=101, 
34%; p<0.0001), followed by responders to PvCSP-P. vivax-like, which were more 
prevalent than those responding to PvCSP-VK247 (p=0.0015) and to PvCSP-Ct 
(p=0.0011) (Figure 2c). Despite differences observed in frequencies of IgG 
responders, the magnitude of IgG responses was similar among responders to 
PvCSP recombinant proteins. The average RI of responders against PvCSP-VK210 
(1.84 ± 0.72), PvCSP-VK247 (1.86 ± 0.77), PvCSP-P. vivax-like (1.96 ± 0.95) and 
PvCSP-Ct (1.74 ± 0.65) did not differ statistically (p>0.05) (Figure 2d). All samples 
from healthy Control group were negative to all four recombinant proteins. 
Two hundred and seven of individuals (69%) presented IgG antibodies against at 
least one of recombinant proteins, from these 92% (190) have reported previous P. 
vivax infections, including ongoing infections 23,7% (49). Only 17 individuals never 
reported previous P. vivax episodes and 4 of these (2%) were infected with P. 
falciparum. Among responders, 16.9% of individuals presented antibodies against all 
four recombinant proteins, 37.7% against three recombinant proteins, 25.6% to two 
of the recombinant proteins and 19.8% to only one antigen. Inside the group of 
responders to only one recombinant protein (n=41), PvCSP-VK210 represented 
56,1%. Moreover, focusing on humoral immune response to PvCSP variants, 28.5% 
of responders to at least one of recombinant proteins, responds to the three PvCSP-
variants, 14.5% to PvCSP-VK210 and PvCSP-VK247, 28.5% to PvCSP-VK210 and 
PvCSP-P. vivax-like, 3.4% to PvCSP-VK247 and PvCSP-P. vivax-like, 14% responds 
only to PvCSP-VK210, 2.9% only to PvCSP-VK247 and 7.7% only to PvCSP-P. 
vivax-like, as demonstrated in figure 3.  
In order to evaluate if the infection status could change the antibody profile of 
recognition, we also assessed the frequency and magnitude of antibodies against the 
recombinants by the presence/absence of P. vivax at the time of blood collection. 
Among individuals living in endemic areas, 31% (n=92) did not present antibodies to 
any of the recombinant proteins, these individuals include 28 infected P. vivax 
individuals. We have also selected P. vivax infected and non-infected individuals 
inside the group of 207 recombinant protein responders and compared their 
frequencies and IgG reactivity indexes. We found out higher frequencies of IgG 
responders to PvCSP-VK210 and PvCSP-Ct in non-infected individuals (p= 0.0086 
and p= 0.0117, respectively). However, IgG magnitude was similar between these 
two groups (supplementary figure S1).   
 
Evaluation of IgG subclass profile against PvCSP variants 
 
We assessed the overall subclass distribution of the IgG antibody (IgG1, IgG2, IgG3, 
IgG4) responses among responders to each recombinant protein. Among 177 
responders to PvCSP-VK210, 149 individuals (84.2%) presented IgG1 antibodies. 
This is higher than the frequencies of IgG2 (67.8%, p=0.0005), IgG3 (43.5%, 
p<0.0001) and IgG4 (5.6%, p<0.0001). Similarly, responders to PvCSP-VK247 
(n=102), also had a prevalence of IgG1 (70.6%) over the other IgG subclasses 
(p<0.0001), followed by IgG2 (33.3%) and similar frequencies of IgG3 (13.7%) and 
IgG4 (17.6%) (p=0.0015 and p=0.0155, respectively, when compared to IgG2) 
responders. In contrast, among responders to PvCSP-P. vivax-like (n=141), IgG3 
was the most frequent subclass, representing 76.6% of responders (p<0.0001 as 
compared to other subclasses), while 33.3%, 19% (p=0.0063) and 25.5% of this 
group presented IgG1, IgG2 and IgG4 specific antibodies respectively. Lastly, among 
responders to the C-terminal region of PvCSP (PvCSP-Ct, n= 101), we observed a 
minor frequency of responders to IgG4 (7.9%) than to all other subclasses 
(p<0.0001). Moreover, similar frequencies of responders to IgG3 (58.4%) and IgG2 
(47.5%) were observed, both of them, higher than the observed frequency of 
responders to IgG1 (25.7%) (p<0.0001 and p=0.0021, respectively) (Figure 4a).  
 
Concerning the magnitude of response of each IgG subclass against PvCSP, the RIs 
ranged from 0.15 to 34.32. Focusing on subclasses profile against PvCSP-VK210, 
IgG1 responders presented higher RIs (median= 2.97; interquartile range= 1.86 – 
4.83) than IgG2 (median= 1.86; interquartile range= 1.39 – 2.93, p<0.0001), IgG3 
(median= 1.2; interquartile range= 1.1 – 1.6, p<0.0001) and IgG4 responders 
(median= 1.39; interquartile range= 1.07 – 1.79, p=0.0002), while responders to IgG3 
and to IgG4 presented similar RI and both subclasses had lower RIs than IgG2 
(p<0.0001 and 0.018, respectively). Moreover, despite the high prevalence of IgG1 
responders against PvCSP-VK247, the RIs of IgG1 responders (median= 1.43; 
interquartile range= 1.2 – 2.28) were only higher than IgG2 (median= 1.28; 
interquartile range= 1.07 – 1.66; p=0.0359) and IgG4 (median= 1.23; interquartile 
range= 1.08 – 1.69; p=0.0436), although RIs of IgG3 responders (median= 1.2; 
interquartile range= 1.07 – 2.34) were similar to other IgG subclasses. Besides, 
concerning the reactivity to PvCSP-P. vivax-like, the RIs of IgG3 responders 
(median=1.76; interquartile range= 1.31 – 2.38) were higher than that of IgG1 
(median= 1.15; interquartile range= 1.09 – 1.3, p<0.0001), of IgG2 (median= 1.04; 
interquartile range= 1.02 – 1.15, p<0.0001) and of IgG4 (median= 1.23; interquartile 
range= 1.05 – 1.54, p<0.0002). Finally, considering the responsiveness to PvCSP-C-
terminal region, we observed no differences among the RIs of responders to IgG1 
(median= 1.16; interquartile range=1.08 – 1.39); IgG2 (median= 1.29; interquartile 
range= 1.12-1.82); IgG3 (median= 1.15; interquartile range= 1.06 – 1.25) and IgG4 
(median= 1.18; interquartile range= 1.06 – 1.73). 
 
Furthermore, a higher IgG1 RI response against PvCSP-VK210 was observed when 
compared to RI of IgG1 against PvCSP-VK247 (p<0.0001) and to PvCSP-P.vivax-
like (p<0.0001), and a higher IgG3 reactivity to PvCSP-P.vivax-like than to PvCSP-
VK210 (p<0.0001) (Figure 4b). When we selected and compared infected and non-
infected responders to each subclass per recombinant protein we did not find 
differences in frequencies and reactivity indexes (supplementary figure S1).  
 
Evaluation of associations between exposition/protection factors and humoral 
immune response to PvCSP.  
In order to investigate the influence of epidemiological parameters on the 
responsiveness to PvCSP, we compared the epidemiological data of responders and 
non-responders to each one of the PvCSP recombinant proteins. Responders to 
PvCSP-VK210, VK247 and P. vivax-like presented higher median of age (p=0.007; 
p=0.003; p=0.007, respectively) and time of residence in endemic area (p=0.005; 
p=0.005 and p=0.015, respectively) than non-responders to each protein. No 
statistical difference was found between responders and non-responders to PvCSP-
Ct (Figures 5a, b, c and d). 
 
To identify factors associated with the magnitude of response to each antigen, we 
investigated the existence of correlations between RIs against recombinant proteins 
and epidemiological data. Firstly, we observed a tendency of correlation between age 
and time of residence on endemic area with RIs of IgG antibodies against PvCSP-
VK210 (p=0.007, r=0.159 and p=0.005, r=0.165; respectively) and against PvCSP-P. 
vivax-like (p=0.026, r=0.131 and p=0.037, r=0.124; respectively). In addition, RIs of 
IgG antibodies against PvCSP-VK247 presented a tendency of correlation with the 
number of previous malaria episodes (NPME) (p=0.024, r=0.135).  
 
Besides, searching for associations between subclass profile against PvCSP-variants 
and epidemiological data, we identified that the number of previous malaria episodes 
positively correlated with the IgG1 levels to PvCSP-VK210 (p=0.008, r=0.204) and 
IgG3 levels to PvCSP-VK247 (p=0.0007, r=0.278). For PvCSP-P.vivax-like 
responders, the RIs of IgG2 were directly correlated with both, age (p=0.002, r= 
0.266) and time of residence in endemic area (p=0,001, r=0.294). No significant 
correlations were observed between epidemiological data and humoral response to 
PvCSP-Ct. 
 
Characteristics of Responders to the Three Major PvCSP Variants  
 
In order to investigate the effect of responsiveness against all PvCSP variants on 
protection against malaria, we compared the epidemiological data of responders to 
all three PvCSP variants (VK210, VK247 and P. vivax-like ; N=59) with those of 
individuals who did not respond to at least one of these variants (N=240). Samples of 
responders to three variants have a significantly longer time of residence in endemic 
area (TREA) (median = 38; interquartile range = 24.5 – 52.5), on average 6 years 
more than individuals that did not respond (median = 30; interquartile range = 21 - 
44) (p=0.017). Moreover, the RIs of cytophilic antibodies of responders to three 
PvCSP variants inversely correlated with months since the last malaria (MSLM). 
Reactivity indexes of IgG1 against PvCSP-VK210 (p=0.047; r = -0.276), IgG1 
(p=0.041; r = -0.285) and IgG3 (p=0.029; r = -0.303) against PvCSP-P. vivax-like 
inversely correlated with MSLM (Figures 6a, 6c and 6d). However, as it is shown in 
figure 6b, RIs of IgG1 against PvCSPVK247 directly correlated with this same 





Previous works have proposed that CSP variants of P. vivax, besides having 
variations in the repetitive portion of the protein, can differ from each other in aspects 
such as geographical distribution, intensity of transmission, vectorial competence, 
immune response, response to treatment and drug resistance 23,27-29. Such aspects 
must be considered to P. vivax vaccine development 22. Therefore, multidisciplinary 
studies characterizing PvCSP variants epidemiology may advance in the 
development of an effective vaccine against P. vivax. 
 
In our study, we evaluated and characterized the humoral IgG response to the 
PvCSP variant repeats (VK210, VK247 and P. vivax-like) and the C-terminal region, 
in a population consisting of 299 individuals naturally exposed to P. vivax malaria, 
living in Acre, a state of the malaria endemic Brazilian Amazon. From 207 responders 
to at least one of recombinant proteins, 190 described previous P. vivax infections 
and just 49 were infected with this species. This result suggests that production of 
antibodies against PvCSP extends for past infections. This feature was previously 
demonstrated in a study conducted by Longley et al at a low transmission region in 
Thailand, where the majority of study population was not infected with P. vivax but 
still presented detectable IgG levels30. Other study of a yearlong cohort also 
demonstrated IgG positivity and magnitude persistence over 1 year period in 
absence of qPCR-detectable blood stage P. vivax infections.31 Our results 
demonstrated that, PvCSP-VK210 presented the highest prevalence of responders, 
followed by PvCSP-P. vivax-like and PvCSP-VK247. Frequency profiles were already 
described in different Amazon regions and they are consistent with our results. 
Oliveira-Ferreira et al have observed the same profile of IgG responders to these 
PvCSP variants (More responders to PvCSP-VK210, followed by PvCSP-P. vivax-
like and PvCSP-VK247) in Candeias do Jamari in Rondônia state, in 2004 32. 
However, the mentioned paper found lower frequencies in comparison to our study, 
which could be related to the use of synthetic peptides as antigens in their ELISA 
assays. In 2000, Machado and Póvoa evaluated the distribution of PvCSP variants of 
P. vivax from three endemic areas (Belém, Macapá and Porto Velho), and again 
found a dominance of prevalence similar to ours 33. Years later, Storti-Melo et al 
assessed the frequency of PvCSP variants using PCR/RFLP samples from five 
states of the Brazilian Amazon, Acre, Amapá, Mato Grosso, Pará and Rondônia.  
Again the profile of distribution of the variants was similar to ours 34. Among facts that 
may explain observed prevalences, we highlight the distinct susceptibility of 
Anopheles mosquitoes to different PvCSP variants, which depends on the 
recognition of specific ligands of the peritrophic matrix by ookinete surface proteins, 
triggering migration or entrapment of the parasite 35. A study that used dissected 
blood fed infected mosquitoes and ELISA assays, demonstrated a preferential 
development of PvCSP-VK210, as compared to that of PvCSP-VK247, in An. 
aquasalis and An. darlingi, in the state of Pará 27. Moreover, frequencies of IgG 
responders to PvCSP recombinant proteins corroborate the co-circulation of all three 
P. vivax variants in Amazon region 23,24,36. Besides, the higher frequency of 
antibodies to VK210 are in according to studies that described this variant as the 
most common in Amazon, while VK247 was rarely reported as single infection 22,23,34. 
In our study we found 28 P. vivax infected patients that are non-responders to 
recombinant proteins and this was already described in literature. In 2018, Oliveira-
Ferreira performed a study to evaluate seroprevalence to CSP and demonstrated 
that not only Brazilian naturally exposed individuals but also P. vivax infected ones, 
were unresponsive to peptides of this protein. In this same study, two specific allelic 
groups were associated with absence of antibodies against PvCSP (HLA-DRB1*01 
and HLA-DQB1*05) 37. In this scenario, we believe our findings can be explained by 
well documented associations of the immune response with specific HLA alleles 
against malaria antigens 38,39. 
  
Concerning the functionality of the IgG subclasses, we did observe a predominance 
of cytophilic antibodies to PvCSP variants, once that IgG1 was the prevailing 
subclass against VK210 and VK247, and IgG3 was the principal IgG subclass of 
antibodies to P. vivax-like. Interestingly, this preponderance of cytophilic antibodies 
was previously described to PvCSP and PvTRAP, suggesting that this profile could 
be associated to the adaptive immune response against preerythrocyte stage 
proteins 40. Moreover, in places where malaria is endemic and the local population 
has had several malaria episodes through the years, there are evidences that the 
premonition (immune condition characterizing clinical protection as reflected by the 
absence of fever and presence of infection at low densities of parasitemia) is reached 
after repeated infections, due to the presence of both cytophilic antibodies (IgG1 and 
IgG3) and memory cells 41-43. In this context, despite that we not found any significant 
association between cytophilic antibodies and protection in this study, we believe that 
these antibodies could act in synergy with other antibodies against preerythrocytic 
targets, promoting a protective effect. However, it is important to highlight that 
previous works have already demonstrated heterologous reactivity occurring in 
antibodies elicited against CSP antigens of P. vivax and P. falciparum 44, so, despite 
the fact that the majority of our recombinant protein responders got in touch with P. 
vivax, we can’t affirm that these antibodies are exclusively to P. vivax.   
 
For the purpose of elucidating the influence of epidemiological factors in humoral 
response to PvCSP variants and C-terminal region, we correlated induced RI’s of IgG 
and its’ subclasses with the studied population parameters. We found out that IgG 
reactivity indexes of PvCSP-VK210 and PvCSP-P. vivax-like presented a trend to 
increase with time of exposition to infection. This tendency could be explained by 
both, the preferential development of PvCSP-VK210 in predominant species of 
anopheles mosquitoes in Amazon and the widely geographical distribution of these 
variants when compared to PvCSP-VK247 (suggested to have a lower geographic 
adaptation in Brazil) 27,34. These data may explain why people living longer in these 
endemic regions tend to have higher IgG reactivity indexes against PvCSP-VK210 
and PvCSP-P. vivax-like, since they get in touch more frequently with these two 
variants. On the other hand, IgG reactivity indexes of PvCSP-VK247 presented a 
tendency of correlation with the number of previous malaria episodes, which is also 
coherent with the aforementioned condition, since individuals that have more 
infections will probably have more chances to get in touch with this less 
geographically distributed variant. In our results we have considered three areas as a 
single one. However, looking separately to these areas, Mâncio Lima and Cruzeiro 
do Sul demonstrate a similar/higher prevalence of the variant PvCSP-VK247 on 
PvCSP-P. vivax-like as a previous work has demonstrated in other Brazilian endemic 
areas24. 
 
We have then checked possible correlations between subclass reactivity indexes and 
epidemiological parameters. Our findings suggest a cumulative effect on IgG1 
reactivity indexes against PvCSP-VK210 as a result of previous malaria episodes. On 
the other hand, PvCSP-VK247 IgG3 RI’s presented a direct correlation with the 
NPME. Differently of the PvCSP variants, the RI’s of IgG and its’ subclasses able to 
recognize the C-terminal region of the protein were not able to correlate with any of 
the epidemiological parameters described. These findings are consistent with those 
reported by Arévalo-Herrera describing high levels of cytophilic antibodies capable to 
recognize fragments from both PvCSP N-terminal and repeated regions, based on 
immunizations with long synthetic peptides in phase I clinical assays, while the C-
terminal region was not immunogenic in humans 45. In addition, despite immunogenic 
in mice, N or C terminals only (i.e. lacking either VK210 or 247 repeat sequences) 
also failed to induce protective immunity 26. Since Kurtovic et al pointed complement 
activation by antibodies as an important mechanism of anti-sporozoite human 
immunity, one of the possible mechanisms that might explain the non-immunogenic 
profile of PvCSP-Ct is by means of the complement fragment C3d, capable to limit 
the anti-CSP C-terminal flanking sequence-specific antibody response by masking 
epitopes in this region of the molecule. Thus, C3d binding to CSP C-terminal region 
may represent a mechanism based on the exploitation of the innate immune 
response by the parasite in order to suppress the development of an acquired 
immune response against a conserved region of the protein 46. 
In agreement with the previous discussed results, comparison of epidemiological 
parameters of responders and non-responders to each one of the recombinant 
proteins presented statistical differences of age and TREA for the three PvCSP allelic 
variants. Again, only PvCSP-Ct did not present such a difference and induced low 
responses in natural exposure conditions. This finding could suggest that the 
production of specific antibodies against the C-terminal region is not conditioned by 
the TREA or parasite exposure. In fact, the production of antibodies to PvCSP-Ct 
may be related to the ability of each individual's immune system to circumvent a 
possible mechanism of parasite-mediated evasion, like we previously suggested. 
 
From all of the studied population (299) individuals, 59 presented specific IgG 
antibodies to all of PvCSP variants. When compared to individuals that did not 
respond to at least one of the variants, these individuals presented significantly 
longer TREA (mean of 6 years). Furthermore, this same group presents inverse 
correlations between cytophilic RI’s (IgG1 against PvCSP-VK210; IgG1 and IgG3 
against PvCSP-P. vivax-like) and MSLM, suggesting that these specific antibodies 
could, somehow, represent markers of recent infection. On the other hand, only IgG1 
RI’s of PvCSP-VK247 were directly correlated with MSLM, implying that these 
specific antibodies may be important for a protective immune response. 
 
In conclusion, despite the limitations in sample size and study design, our work 
indicates that IgG positivity and magnitude against PvCSP variants can persist from 
past infections in the studied population, even in the absence of an ongoing malaria 
episode. The profile of responders to PvCSP allelic variants and its geographical 
distribution are still compatible with scientific literature, with dominance of PvCSP-
VK210, followed by PvCSP-P. vivax-like and PvCSP-VK247. The immune response 
raised against the recombinant proteins studied here, were mediated, predominantly, 
by cytophilic antibodies, which have a relevant role to trigger a protective immune 
response. Conversely, C-terminal region, does not seem to be the best option in 
vaccine design due its low-immunogenic properties and absence of correlation with 
epidemiological parameters and protection indicatives. Lastly, taking into account the 
limitations of the number of individuals enrolled in our study and the unique features 
of studied population, which is historically exposed to P. vivax and P. falciparum 
simultaneously, we can not exclude the possibility of heterologous reactivity of 
antibodies against P. vivax CSP variants. Therefore, other epidemiological studies 
regarding P. vivax allelic variants in other areas are encouraged and essential to 
address this question and increase the knowledge about the serological landscapes 




Study Area and Volunteers 
The cross-sectional cohort study included 299 individuals from three different 
communities with malaria transmission in Acre state: Cruzeiro do Sul (n=124), 
Guajará (n=87) and Mâncio Lima (n=88). Samples of 53 individuals living in non 
aendemic areas of Rio de Janeiro and never exposed to malaria were the control 
group. Samples and survey data were collected from June to August of 2016. 
Informed consent was obtained from all donors by written declaration. The study was 
reviewed and approved by the Fundação Oswaldo Cruz Ethical Committee and the 
National Ethical Committee of Brazil.  
 
Ethics approval and consent to participate 
Written consent for use of plasma samples and survey data were obtained in 
accordance to the revised Declaration of Helsinki. Both collection and consent 
protocols were under approval of Fundação Oswaldo Cruz Ethical Committee and 




To evaluate the potential influence of clinical and exposure features on immunity 
response against PvCSP variants, the donors were interviewed prior the blood 
sampling. Questions related to personal exposure to malaria, such as time of 
residence in transmission areas, previous malária episodes, use of prophylactic 
measures, symptoms and personal knowledge of malaria transmission were done 
with all study participants. The answers were stored in Epi-Info databank for 
subsequent analysis (Centers for Disease Control and Prevention, Atlanta, GA, 
USA). Written informed consent was obtained from all adult donors or from parents of 
donors in the case of minors. 
 
Malaria Diagnosis and Blood Sampling 
Blood samples were collected by venipuncture in heparin tubes and centrifuged (350 
x g, 10min) to plasma separation and storage at -20°C to ship to Laboratório de 
Imunoparasitologia, Fiocruz – RJ. Thin and thick blood smears were stained and 
analyzed for malaria parasites. The diagnosis were done by examination of 200 fields 
at 1000× magnifications under oil-immersion and two research experts in malaria 
diagnosis examined all slides. Individuals positive for P. vivax and/or P. falciparum at 
the time of blood collection were treated using the chemotherapeutic regimen 
recommended by the Brazilian Ministry of Health. 
 
Recombinant PvCSP Variants Expression in HEK-293T Cells  
 
As previously described by Longley et al 31, the P. vivax sequences used were 
PvCSPVK210 of Belem strain (GenBank accession number P08677), PvCSPVK247 
of Papua New Guinea (GenBank accession number M69059), PvCSPVivax-like of 
Papua New Guinea (GenBank accession number L13724.1) and PvCSP C-terminal 
region from Salvador I strain (NCBI Reference Sequence XP_001613068.1). Each 
one of the domains contained in the multi-variant chimeric recombinant protein used 
in the Rv21 vaccine described by Salman et al 26 was synthesized and codon-









Finally, Vivax-like repeats, with a sequence 3x(APGANQEGGAA),  
3x(APGANQGGGAA), was obtained from the genebank accession number: 
AAA18616. 
  
DNA fragments encoding each of the vCSP regions were cloned in the expression 
vector pHLsec, which is flanked by the chicken β-actin/rabbit β-globin hybrid 
promoter with a signal secretion sequence and with a modification of a C-tag instead 
of a His-tag tail.  
 
For expression and purification of vCSP malarial antigens, the codon-optimized 
coding regions were cloned into the pHLsec vector, as previously described, 47 which 
is flanked by the chicken β-actin/rabbit β-globin hybrid promoter with a signal 
secretion sequence and a C-tag (EPEA). The pHLsec plasmids (500 μg) were 
transfected in HEK-293 cells using polyethyleneimine (PEI) in roller bottles (surface 
area of 2,125 cm2) under standard cell culture conditions. Five days after 
transfection, cells were discarded and media was filtered through 0.22 μM disposable 
filters. The secreted protein was purified from the supernatant by affinity 
chromatography (C-tag column), using the Äkta Start chromatography system and 
eluted with 2.0 M MgCl2 and 20 mM Tris, pH 7.0.  Finally, the eluted protein was 
dialysed using Slide-A-LyzerTM cassette (Fisher Scientific) against 1X PBS. 
 
Western Blot 
Supernatants from transfected HEK293 cells were boiled at 100°C for five minutes in 
laemli buffer. Equal amounts cell supernatants were resolved by SDS/PAGE and 
transferred to PVDF membranes. Blots were blocked with 1X PBS-Tween- 5% milk 
and incubated with an anti-C-Tag antibody (CaptureSelect™ Biotin Anti-C-tag 
Conjugate at 1:2000 dilution, supernatants from a MRA-185 hybridoma cell line 
(2E10.E9) that recognize the VK247 repeats, and supernatants from a MRA-184 
hybridoma cell line (2F2) that recognize the VK210 repeats. followed by incubation 
with HRP-conjugated secondary antibody (1:5000). Chemiluminescence (Perkin-




Anti-PvCSP specific antibodies against recombinant VK210, VK247, Vivax-like and C 
terminal region (CT), were evaluated by enzyme-linked immunosorbent assay 
(ELISA) as previously described by Matos et al 48. Briefly, MaxiSorp 96-well plates 
(Nunc, Rochester, NY, USA) were coated overnight with 1.0 µg/ml of each 
recombinant protein. Plates were washed and blocked for 1 h at 37°C. After blocking, 
plasma samples (1:100 in PBS-Tween-BSA 5%) were incubated in duplicate wells 
during 1h. After three washing steps, bound antibodies were detected with anti-
human IgG-PE (Sigma, St. Louis) and followed by addition of o-phenylenediamine 
and hydrogen peroxide. Plates were read at 492 nm using a SpectraMax 250 ELISA 
reader (Molecular Devices, Sunnyvale, CA, USA). The results for total IgG were 
expressed as reactivity indexes (RIs), which were calculated by the mean optical 
density (O.D.) of an each tested sample divided by the cut-off, number expressed by 
the mean optical density of 10 non-exposed control individuals’ samples plus 3 
standard deviation (cut-offs values: VK210 = 0.208, Vivax-like = 0.268, VK247 = 
0.260 and Ct = 0.245). These 10 non-exposed control individuals’ corresponded to 
10 higher DO’s found in 53 control individuals tested (VK210 = 0.126; 0.131; 0.137; 
0.143; 0.146; 0.146; 0.149; 0.153; 0.183; 0.184; Vivax-like = 0.147; 0.175; 0.185; 
0.189; 0.191; 0.202; 0.210; 0.210; 0.220; 0.230; VK247 = 0.139; 0.146; 0.149; 0.168; 
0.172; 0.178; 0.188; 0.193; 0.215; 0.220; Ct = 0.129; 0.131; 0.137; 0.148; 0.156; 
0.182; 0.183; 0.189; 0.192; 0.196). Subjects were scored as responders to PvCSP 
variants if the RI of IgG against each one of the recombinant proteins was higher 
than 1. Additionally, the RIs of IgG subclasses for each one of the proteins, were 
evaluated on responders of each PvCSP variant. The same method was done, using 
peroxidase-conjugated goat anti-human IgG1, IgG2, IgG3, and IgG4 (Sigma, St. 
Louis) (cut-offs – VK210 IgG1 = 0.158, IgG2 = 0.168 , IgG3 = 0.194 and IgG4 = 
0.315, Vivax-like IgG1 = 0.060, IgG2 = 0.053, IgG3 = 0.110 and IgG4 = 0.065, VK247 
IgG1 = 0.234, IgG2 = 0.337, IgG3 = 0.288 and IgG4 = 0.439 and Ct IgG1 = 0.161, 
IgG2 = 0.308, IgG3 = 0.191 and IgG4 = 0.284). 
 
Statistical Analysis 
Statistical analyzes were done in GraphPad Prism 5.0 for Windows (GraphPad 
Software, Inc.). Normality test were done in all variables using the one-sample 
Kolmogorov–Smirnoff test. The Dunn’s test was used to compare RIs of IgG against 
recombinant PvCSP variants in studied groups. Uncorrected Fisher’s plus LSD was 
done to access the differences in proportions of IgG, IgG subclass. Correlations 
between immune response and epidemiological parameters were evaluated by 
Spearman rank test. A two-sided p value <0.05 was considered significant. 
 
Data Availability 
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Figure 1. Expression of vCSP malarial antigens for protein production. (a) 
Schematic representation of the vivax CSP protein. The C-term portion (yellow) 
without its transmembrane domain, as well as the 3 different allelic variants from the 
central repeat region (VK217, VK247 and V-like) were fused to the c-tag epitope 
(EPEA) to allow purification using a c-tag affinity column (red). Black color represents 
the exogenous signal sequence contained in the expression plasmid construct. (b) 
Synthetic DNA sequences  carrying such malarial antigens were extracted by double 
enzymatic digestion (AgeI and KpnI), red asterisk represents the specific size for 
each construct that were cut from the agarose gel,  followed by ligation to the 
backbone plasmid pHLsec. (c) Enzymatic restriction from the PhLsec plasmids after 
ligation with the malarial antigens. Red asterisk represents the specific size of the 
coding regions and black asterisk represents the PhLSec backbone. PhLSec plasmid 
were transfected into HEK293 cells and supernatant was recovered 4 days after 
transfection. 10 ml of each of the supernatants was subjected to SDS-PAGE and 
western blot against the anti-C-Tag (d), the anti-210 (e), and the anti-247 (f) 
antibodies. 
 
Figure 2: Humoral response against PvCSP recombinant proteins. Frequencies 
of IgG responders in each studied locality (a); reactivity indexes of responders in the 
three studied localities (b); overall frequencies of IgG responders (c) and overall 
reactivity indexes of IgG antibodies of responders (d) to each recombinant protein 
derived from PvCSP. In Fig 2a and c, each bar represents the frequency of 
responders to one of the recombinant proteins (PvCSP-VK210: orange bar; PvCSP-
VK247: green bar; PvCSP-P.vivax-like: gray bar and PvCSP-Ct: purple bar). Fig 1b 
and d, each point represents an individual RI against PvCSP recombinant proteins 
(PvCSP-VK210: orange points; PvCSP-VK247: green points; PvCSP-P.vivax-like: 
gray points and PvCSP-CT: purple points). Black bars on Fig 2b and d represent 
values of median and interquartile range. RIs higher than 1 are considered 
responders to the recombinant protein. Frequencies of responders were compared 
by Fisher´s exact test and RIs were compared by Mann-Whitney test. Significant 
differences were indicated by *. (*) p<0.05; (**) p<0.005; *** p<0.0005. 
 
Figure 3: Venn diagram of responders to at least one of the recombinant 
proteins. In this diagram, values of N and the percentage of responders are 
demonstrated. Values marked with colors represent individuals that respond 
exclusively to the indicated protein (orange PvCSP-VK210, green PvCSP-VK247 and 
gray PvCSP-P.vivax-like). Values in black represent individuals that respond to two 
or three of the recombinant proteins according to the circles in which values are 
inserted.  
 
Figure 4: Frequency of IgG subclass responders (a) and their reactivity indexes 
(b) against the recombinant PvCSP proteins in the studied population. Points 
represent an individual RI against PvCSP recombinant proteins (PvCSP-VK210: 
orange points; PvCSP-VK247: green points; PvCSP-P.vivax-like: gray points and 
PvCSP-CT: purple points). The red traced line represents the cutoff, RIs higher than 
1 are considered responders to the recombinant protein. Frequencies of responders 
were compared by Fisher´s exact test and RIs were compared by Mann-Whitney test. 
Significant differences among subclasses were indicated by * and significant 
differences among responsiveness to each protein were indicated by +; (*) p<0.05; 
(**) p<0.01; (***; +++) p<0.001. In this figure # means that the subclass is different 
from all the others against the same protein.  
 
Figure 5: Comparison of epidemiological parameters between responders and 
non-responders to each PvCSP recombinant protein. TREA = Time of residence 
in endemic area (years), NPME = Number of previous malaria episodes, MSLM = 
Months since last malaria and TRPA = Time of residence in the present address 
(years). Epidemiological data of responders and non-responders to each one of the 
recombinant proteins were compared by Mann-Whitney test.   
 
 
Figure 6: Correlation of RIs of cytophilic IgG subclasses with months since the 
last malaria (MSLM). (a) Correlation of IgG1 RIs against PvCSP-VK210 with MSLM. 
(b) Correlation of IgG1 RIs against PvCSP-VK247 with MSLM. (c) Correlation of 
IgG1 RIs against PvCSP-P. vivax-like with MSLM. (d) Correlation of IgG3 RIs against 





















    CZSa     GJb   MLc    Total 
  (n=124)   (n=87) (n=88)   (n=299) 
Gender – N (%) 
Male 65 (52.4%) 45 (51.7%) 44 (50%) 154 (51.5%) 
Female 59 (47.6%) 42 (48.3%) 44 (50%) 145 (48.5%) 
Malaria exposure - Median (IR) 
A.P.I. 55,5 42,5 107,2 61,4 
Age (years) 29.5 (20-45) 33 (22-50) 33.5 (23-42.5) 32 (22 - 47) 
Years of residence on endemic area 29 (19.5-44) 33.5 (23-50) 32.5 (21–43) 31 (21 - 47) 
Years of residence in the present address 20 (6-36) 18 (3-29)c* 27.5 (12.5-38.5)b* 20 (5-36) 
Months since the last malaria episode 2.5 (0-60)b** 12 (4-48)a**/c*** 3.5 (0-22)b*** 5 (0-36) 
Number of malaria episodes on the last year  1 (0-1) 0 (0-1) 1 (0-1.5) 0.5 (0-1) 
Number of previous malaria episodes 6 (2-12) 5 (2-10) 10 (5-20) 7 (3-15) 
Species causing previous episodes – N (%)    
P. vivax 23 (19%) 16 (18%) 17 (19%) 56 (19%) 
P. falciparum 10 (8%) 6 (7%) 0 (0%) 16 (5%) 
P. vivax and P. falciparum  68 (55%) 51 (59%) 67 (76%) 186 (62%) 
Never infected  1 (0.8%) 6 (7%) 0 (0%) 7 (2%) 
Not reported  21 (17%) 8 (9%) 5 (6%) 34 (11%) 
Diagnosis – N (%)   
P. vivax 39 (31.5%) 10 (11.5%) 24 (27.3%) 73 (24.4%) 
P. falciparum 25 (20.2%) 6 (6.9%) 10 (11.4%) 41 (13.7%) 
Mixed  0 (0%) 1 (1.1%) 3 (3.4%) 4 (1.3%) 
Negative 60 (48.4%)b** 70 (80.5%) a**/c** 51 (58%)b** 181 (60.5%) 
 
Table 1: Epidemiological features of the study population. Values of A.P.I. 
(annual parasitic index), Age, Years of residence in endemic areas, Years of 
residence in the present address, Months since the last malaria, Number of malaria 
episodes on the last year and number of previous malaria episodes represent the 
median (interquartile range). Frequencies were compared by Fisher’s test, and other 
epidemiological parameters were compared by Mann–Whitney test. Upper scripted 
letters (a, b, c) indicate the studied populations (CZS = Cruzeiro do Sul; ML = GJ = 
Guajará and Mâncio Lima, respectivelly) and statistical differences were represented 
by *(*) p<0.05; (**) p<0.005; *** p<0.0005. 
 






